Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Predicting and Understanding Cancer Response to Treatment

(2018) Maurizio Callari et al.   DISEASE MARKERS

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1

(2018) Erik A. Dill et al.   MODERN PATHOLOGY

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

(2018) Yiting Wang et al.   Frontiers in Pharmacology

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

(2018) Shisuo Du et al.   OncoImmunology

Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1

(2017) Hui Li et al.   HEPATOLOGY

Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy

(2017) Huan Bin Wang et al.   Journal of Digestive Diseases

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

(2017) P. Mohr et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

(2017) Elizabeth R Plimack et al.   LANCET ONCOLOGY

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

(2017) Yohei Masugi et al.   Cancer Immunology Research

PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

(2017) Huanbin Wang et al.   OncoImmunology

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

PD-1 as an Immune Modulatory Receptor

(2014) Sheng Yao et al.   CANCER JOURNAL

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

(2014) G. K. Philips et al.   INTERNATIONAL IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

A roadmap to generate renewable protein binders to the human proteome

(2011) Karen Colwill et al.   NATURE METHODS

Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

(2010) T. Schatton et al.   CANCER RESEARCH

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis

(2008) Boryana K. Popivanova et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE